Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC).

Inclusion Criteria: * ≥18 years * Intrahepatic CCC, proven by histology or by typical morphology in cross sectional imaging and elevated tumor markers (CEA or CA 19-9) * Tumor confined to the liver * At least one measurable lesion in magnetic resonance imaging (MRI) * Tumor load ≤ 50% * Preserved liver function (Child Pugh A and B) * ECOG performance status ≤2 Exclusion Criteria: * Patients feasible for curative treatment (e.g. resection or local ablation) * Previous TACE or SIRT * Prior Chemotherapy * Child Pugh stage C * ECOG Performance Status \>1 * Tumor involvement \>50% of the liver * Extrahepatic tumor * Serum Bilirubin \>2.0 mg/dl; Serum Albumin 2.8 g/dl, Serum Creatinine \>2 mg/dl; Leukocytes \<3000/ml; Thrombocytes \<50000/ml * Clinically apparent ascites (ascites only in CT/MRI is no exclusion criteria) * Esophageal bleeding during the last 3 months * Hepatic encephalopathy * Transjugular intrahepatic portosystemic shunt (TIPS) * Infiltration or occlusion of the main portal vein * Hepatofugal blood flow in the portal vein * Hepatopulmonary shunt ≥ 20% in the macroaggregated albumin scan (MAA-scan) * Contraindications against angiography * Pregnancy